- Home
- ACRS vs EML Comparison
ACRS vs EML Comparison
Compare ACRS & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- EML
- Stock Information
- Founded
- ACRS 2012
- EML 1858
- Country
- ACRS United States
- EML United States
- Employees
- ACRS N/A
- EML N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- EML Industrial Machinery/Components
- Sector
- ACRS Health Care
- EML Consumer Discretionary
- Exchange
- ACRS Nasdaq
- EML Nasdaq
- Market Cap
- ACRS 165.7M
- EML 144.5M
- IPO Year
- ACRS 2015
- EML N/A
- Fundamental
- Price
- ACRS $1.53
- EML $22.03
- Analyst Decision
- ACRS Strong Buy
- EML
- Analyst Count
- ACRS 9
- EML 0
- Target Price
- ACRS $9.25
- EML N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- EML 8.4K
- Earning Date
- ACRS 08-11-2025
- EML 08-05-2025
- Dividend Yield
- ACRS N/A
- EML 2.00%
- EPS Growth
- ACRS N/A
- EML N/A
- EPS
- ACRS N/A
- EML N/A
- Revenue
- ACRS $17,777,000.00
- EML $271,440,503.00
- Revenue This Year
- ACRS N/A
- EML $1.56
- Revenue Next Year
- ACRS $8.11
- EML $7.00
- P/E Ratio
- ACRS N/A
- EML $10.98
- Revenue Growth
- ACRS N/A
- EML 8.15
- 52 Week Low
- ACRS $1.05
- EML $19.06
- 52 Week High
- ACRS $5.17
- EML $35.03
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- EML 37.94
- Support Level
- ACRS $1.46
- EML $22.27
- Resistance Level
- ACRS $1.86
- EML $23.70
- Average True Range (ATR)
- ACRS 0.12
- EML 0.55
- MACD
- ACRS -0.02
- EML -0.13
- Stochastic Oscillator
- ACRS 17.54
- EML 0.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.